DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Somatuline Depot (Lanreotide Acetate) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

SUMMARY

Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg is a prolonged-release formulation for deep subcutaneous injection containing the drug substance lanreotide acetate, a synthetic octapeptide with a biological activity similar to naturally occurring somatostatin, and water for injection.

Somatuline Depot (lanreotide) Injection 60 mg, 90 mg and 120 mg is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal.


See all Somatuline Depot indications & dosage >>

NEWS HIGHLIGHTS RELATED TO SOMATULINE DEPOT

Published Studies Related to Somatuline Depot (Lanreotide)

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. [2006.11.15]

Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial. [2006.05]

Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. [2005.11]

Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. [2005.07]

Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion. [2004.01]

more >>

Clinical Trials Related to Somatuline Depot (Lanreotide)

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome [Not yet recruiting]

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study [Recruiting]

Treatment of the Dumping Syndrome With Lanreotide Autogel® [Recruiting]

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma [Recruiting]

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer [Not yet recruiting]

more >>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008